Follow
Natalia Baran
Natalia Baran
Assistant Professor, University of Texas, MD Anderson Cancer Center
Verified email at mdanderson.org
Title
Cited by
Cited by
Year
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ...
Nature medicine 25 (12), 1938-1947, 2019
3902019
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
M Daher, R Basar, E Gokdemir, N Baran, N Uprety, AK Nunez Cortes, ...
Blood, The Journal of the American Society of Hematology 137 (5), 624-636, 2021
1752021
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
P Matre, J Velez, R Jacamo, Y Qi, X Su, T Cai, SM Chan, A Lodi, ...
Oncotarget 7 (48), 79722, 2016
1682016
Molecular pathways: hypoxia-activated prodrugs in cancer therapy
N Baran, M Konopleva
Clinical Cancer Research 23 (10), 2382-2390, 2017
1182017
Clonal selection and therapy resistance in acute leukaemias: mathematical modelling explains different proliferation patterns at diagnosis and relapse
T Stiehl, N Baran, AD Ho, A Marciniak-Czochra
Journal of The Royal Society Interface 11 (94), 20140079, 2014
972014
Cell division patterns in acute myeloid leukemia stem-like cells determine clinical course: a model to predict patient survival
T Stiehl, N Baran, AD Ho, A Marciniak-Czochra
Cancer research 75 (6), 940-949, 2015
872015
Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated blood and cord blood–derived NK cells facilitates CAR-like responses against CD30+ malignancies
LN Kerbauy, ND Marin, M Kaplan, PP Banerjee, MM Berrien-Elliott, ...
Clinical Cancer Research 27 (13), 3744-3756, 2021
852021
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, ...
Nature medicine 29 (1), 115-126, 2023
812023
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
L Stuani, M Sabatier, E Saland, G Cognet, N Poupin, C Bosc, FA Castelli, ...
Journal of Experimental Medicine 218 (5), e20200924, 2021
712021
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, ...
Signal transduction and targeted therapy 7 (1), 51, 2022
652022
BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment
S Piya, H Mu, S Bhattacharya, PL Lorenzi, RE Davis, T McQueen, ...
The Journal of clinical investigation 129 (5), 1878-1894, 2019
602019
The rarity of ALDH+ cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients
VT Hoang, EC Buss, W Wang, I Hoffmann, S Raffel, A Zepeda‐Moreno, ...
International journal of cancer 137 (3), 525-536, 2015
532015
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition
K Saito, Q Zhang, H Yang, K Yamatani, T Ai, V Ruvolo, N Baran, T Cai, ...
Blood advances 5 (20), 4233-4255, 2021
412021
Brasil da Costa, FH; Konopleva, M
SB Panina, N Baran
Kirienko, NV A mechanism for increased sensitivity of acute myeloid leukemia …, 2019
332019
Utilizing synergistic potential of mitochondria-targeting drugs for leukemia therapy
SB Panina, J Pei, N Baran, M Konopleva, NV Kirienko
Frontiers in oncology 10, 435, 2020
322020
A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs
SB Panina, N Baran, FH Brasil da Costa, M Konopleva, NV Kirienko
Cell Death & Disease 10 (8), 617, 2019
322019
Differences between healthy hematopoietic progenitors and leukemia cells with respect to CD44 mediated rolling versus adherence behavior on hyaluronic acid coated surfaces
M Hanke, I Hoffmann, C Christophis, M Schubert, VT Hoang, ...
Biomaterials 35 (5), 1411-1419, 2014
312014
TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
B George, H Kantarjian, N Baran, JD Krocker, A Rios
International journal of molecular sciences 22 (19), 10782, 2021
302021
Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
S Herbrich, N Baran, T Cai, C Weng, MJL Aitken, SM Post, J Henderson, ...
Journal for immunotherapy of cancer 9 (7), 2021
282021
Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia
N Baran, A Lodi, Y Dhungana, S Herbrich, M Collins, S Sweeney, ...
Nature communications 13 (1), 2801, 2022
272022
The system can't perform the operation now. Try again later.
Articles 1–20